- Home
- CYRX vs CGEM Comparison
CYRX vs CGEM Comparison
Compare CYRX & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYRX
- CGEM
- Stock Information
- Founded
- CYRX 1999
- CGEM 2016
- Country
- CYRX United States
- CGEM United States
- Employees
- CYRX N/A
- CGEM N/A
- Industry
- CYRX Biotechnology: Pharmaceutical Preparations
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- CYRX Health Care
- CGEM Health Care
- Exchange
- CYRX Nasdaq
- CGEM Nasdaq
- Market Cap
- CYRX 438.7M
- CGEM 482.7M
- IPO Year
- CYRX N/A
- CGEM 2021
- Fundamental
- Price
- CYRX $8.77
- CGEM $7.93
- Analyst Decision
- CYRX Strong Buy
- CGEM Strong Buy
- Analyst Count
- CYRX 10
- CGEM 7
- Target Price
- CYRX $11.70
- CGEM $26.57
- AVG Volume (30 Days)
- CYRX 1.1M
- CGEM 342.2K
- Earning Date
- CYRX 08-05-2025
- CGEM 08-07-2025
- Dividend Yield
- CYRX N/A
- CGEM N/A
- EPS Growth
- CYRX N/A
- CGEM N/A
- EPS
- CYRX 1.35
- CGEM N/A
- Revenue
- CYRX $237,879,000.00
- CGEM N/A
- Revenue This Year
- CYRX N/A
- CGEM N/A
- Revenue Next Year
- CYRX $9.08
- CGEM N/A
- P/E Ratio
- CYRX $6.49
- CGEM N/A
- Revenue Growth
- CYRX 24.93
- CGEM N/A
- 52 Week Low
- CYRX $4.58
- CGEM $6.85
- 52 Week High
- CYRX $9.48
- CGEM $19.89
- Technical
- Relative Strength Index (RSI)
- CYRX 57.54
- CGEM 52.82
- Support Level
- CYRX $8.39
- CGEM $7.50
- Resistance Level
- CYRX $9.05
- CGEM $8.32
- Average True Range (ATR)
- CYRX 0.54
- CGEM 0.39
- MACD
- CYRX 0.00
- CGEM 0.04
- Stochastic Oscillator
- CYRX 69.23
- CGEM 72.73
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.